Stone X Group Inc. Vir Biotechnology, Inc. Transaction History

Stone X Group Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$23.2 - $27.29 $1,693 - $1,992	73 Added 0.63%	11,678 $286,000
Q1 2023 May 11, 2023	SELL	$22.26 - $30.85 $3,339 - $4,627	-150 Reduced 1.28%	11,605 $270,000
Q4 2022 Feb 10, 2023	SELL	$19.96 - $28.22 $6,986 - $9,877	-350 Reduced 2.89%	11,755 $298,000
Q3 2022 Nov 08, 2022	SELL	$18.26 - $31.1 $13,968 - $23,791	-765 Reduced 5.94%	12,105 $233,000
Q2 2022 Jul 27, 2022	BUY	$19.08 - $26.7 $245,559 - $343,629	12,870 New	12,870 $328,000
Q1 2022 May 11, 2022	SELL	$21.19 - $40.01 $360,251 - $680,210	-17,001 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$30.97 - $54.03 $65,346 - $114,003	-2,110 Reduced 11.04%	17,001 $712,000
Q3 2021 Oct 20, 2021	SELL	$34.9 - $54.54 $35,598 - $55,630	-1,020 Reduced 5.07%	19,111 $832,000
Q2 2021 Aug 06, 2021	BUY	$38.75 - $51.0 $14,996 - $19,737	387 Added 1.96%	20,131 $952,000
Q1 2021 Jun 23, 2021	BUY	$26.34 - $83.07 $520,056 - $1.64 Million	19,744 New	19,744 $1.01 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

Stay updated on Stone X Group Inc. with notifications on news.